Article Text


Interstitial lung disease and leflunomide use
  1. V Aiyappan
  1. Senior House Office, Huddersfield Royal Infirmary, Huddersfield, UK; aiyapps{at}

Statistics from

There have been numerous reports of interstitial lung disease associated with the use of the new disease modifying anti-rheumatic drug leflunomide. This epidemiological study examined the risk of developing interstitial lung disease (ILD) in patients on leflunomide.

Data from 62 734 patients with rheumatoid arthritis were examined in a case-control study. The risk of ILD was not higher for patients on leflunomide provided they had no previous methotrexate use or a history of ILD (relative risk (RR) 1.2, 95% confidence interval (CI) 0.4 to 3.1). There was, however, an increased risk of ILD with leflunomide in patients who did have a history of previous methotrexate use or ILD (RR 2.6, 95% CI 1.2 to 5.6).

The use of leflunomide as a disease modifying anti-rheumatic drug is increasing in patients with rheumatoid arthritis and reports of ILD are rising. Respiratory physicians should be aware of the potential for developing ILD.

View Abstract

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.